Report Details:
15 Companies Covered
80 Pages
Diabetes Drug Report Market Highlights
The Diabetes Drug Market size was valued at USD 96.90 Billion in 2025, and the market is projected to grow from USD 100.60 Billion in 2026 to USD 140.70 Billion by 2035, registering a CAGR of 3.80% during the forecast period 2026–2035. Diabetes is one of the major problem across the globe. Diabetes is the metabolic disorder in which there is decrease in the level of insulin which ultimately causes increase in the blood sugar level. Global diabetic drug market is driven because of increasing diabetic population. Beside this governmental initiatives for research and development and rising demand for the better treatment has help in the growth of the market. Lack of awareness and high cost of drugs may responsible for restraining the market.
The major key player for the global diabetic drugs market are Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), Takeda (Japan)
Increasing diabetic population is fueling the growth of the market. Global diabetic drug market is highly competitive market due to presence of many of small and medium companies. Companies are concentrating on introduction of the new drugs having better results.
Eli Lilly and Company is an US headquartered pharmaceutical companies. Many anti diabetic drugs are available in the market Basaglar, Glucagon, Glyxambi, Humalog, Humulin and Trulicity are some of the major products of this company. Trulicity is one of the most successful product of the company. Trulicity revenue in 2016 was increased by 7 %. In 2016, Synjardy has approved by FDA for the treatment of type 2 diabetes.
Novartis is a multinational pharmaceutical company headquartered in Denmark. Victoza, Tresiba, Levemir and NovoLog are some of the major products of the company. Company has recently launched Fiasp which is a fast acting insulin. In Q1 2017 the total sale of company for Diabetes and obesity care was 23,761 million Danish kroner.
Abbott Laboratories is one of the leading pharmaceutical company headquartered in US. Thyrocab, Mixtard and Human Actrapid are the major products of the company used in the treatment of type-2 diabetes. Mixtard an antidiabetic drug is the most selling drug in India.
AstraZeneca is the Swedish multinational pharmaceutical company headquartered in UK. Farxiga and Augmentin are the important productof the company. The companies diabetic product sale in 2016 was $ 2.4 billion which was increased by 11 % compare to 2015. Farxiga’s sale was increased by 72 % and on 2016 it hit $835 million.
Geographically, North America has a dominating market for global diabetic drug market. The crucial reason for the growth of the market is increasing diabetic population. Almost 9.3 % of total America population is suffering from diabetes. Other than this well-developed infrastructure and governmental initiatives for the research and development has help to increase the market. Asia Pacific has the fastest growing market. More than 60% of world diabetic population lives in Asia Pacific region which is the major driving factor for the market.
Segmentation:
Global diabetic drug treatment is segmented on the basis of type of diabetes into type-1 and type-2. On the basis of route of administration they are segmented into oral, intravenous and other. On the basis of drug class they are insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs and others and on the basis of end users they are segmented into hospital, retail pharmacy and other.
On the basis of drug class, Sensitizers are sub segmented into thiazolidinediones and biguanides. Secretagogues are further sub segmented into sulfonylureas and non-sulfonylureas.
Highlights:
- Hospital pharmacies represented 36.3% of revenue in 2025, although digital pharmacy platforms are eroding traditional channel dominance.
- Online pharmacies constitute the fastest-growing channel at a 6.28% CAGR, led by transparent cash-pay pricing models in the United States.
- North America commanded 39.2% of the Diabetes Drug Market in 2025, driven by premium pricing and large employer-sponsored insurance pools.
- Asia-Pacific is set to expand at a 5.95% CAGR through 2035, propelled by government-led diabetes screening drives across China, India, and the Gulf states.
